Batonrouge News Reporter

Hemophilia A Pipeline Insight 2021 by DelveInsight

 Breaking News
  • No posts were found

Hemophilia A Pipeline Insight 2021 by DelveInsight

March 22
20:48 2021
Hemophilia A Pipeline Insight 2021 by DelveInsight

 

Hemophilia A Pipeline” report has been added to DelveInsight

 

“Hemophilia A Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hemophilia A market. A detailed picture of the Hemophilia A pipeline landscape is provided, which includes the disease overview and Hemophilia A treatment guidelines. The assessment part of the report embraces in-depth Hemophilia A commercial assessment and clinical assessment of the Hemophilia A pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hemophilia A collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Download free sample copy of Hemophilia A Pipeline- https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight

 

Hemophilia A: Geography Covered

  • Global

 

Hemophilia A: Overview

Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.

 

Hemophilia A Emerging Drugs

  • Valoctocogene Roxaparvovec (BMN 270)- BioMarin Pharmaceutical
  • LR769- HEMA Biologics/LFB Biotechnologies
  • Concizumab (NN7415)- Novo Nordisk
  • Fitusiran (ALN-AT3,SAR-439774)- Sanofi Genzyme/ Alnylam Pharmaceuticals
  • BIVV001(rFVIIIFc-VWF-XTEN)- Sanofi
  • Marstacimab (PF-06741086)- Pfizer
  • Marzeptacog alfa(Activated)- Catalyst Biosciences
  • OPK88005- OPKO Biologics
  • SB-525- Sangamo Therapeutics/ Pfizer
  • SPK-8011- Spark Therapeutics

 

Hemophilia A: Pipeline Development Activities

  • All of the companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Hemophilia A treatment.
  • Hemophilia A key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Hemophilia A market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

 

Hemophilia A: Report Scope

  • The Hemophilia A report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Hemophilia A across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Hemophilia A therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Hemophilia A research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hemophilia A.

 

Download free sample copy of Hemophilia A Pipeline- https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight

 

Following is the table of content of Hemophilia A pipeline report

  1. Report Introduction
  2. Hemophilia A 
  3. Hemophilia A Current Treatment Patterns
  4. Hemophilia A – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Hemophilia A Late Stage Products (Phase-III)
  7. Hemophilia A Mid Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Hemophilia A Discontinued Products
  13. Hemophilia A Product Profiles
  14. Hemophilia A Key Companies
  15. Hemophilia A Key Products
  16. Dormant and Discontinued Products
  17. Hemophilia A Unmet Needs
  18. Hemophilia A Future Perspectives
  19. Hemophilia A Analyst Review  
  20. Appendix
  21. Report Methodology

 

Hemophilia A: Key Questions

  • What are the current options for Hemophilia A treatment?
  • How many companies are developing therapies for the treatment of Hemophilia A?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Hemophilia A?
  • How many Hemophilia A emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Hemophilia A?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Hemophilia A market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Hemophilia A? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Hemophilia A therapies?
  • What are the clinical studies going on for Hemophilia A and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Hemophilia A?
  • How many patents are granted and pending for the emerging therapies for the treatment of Hemophilia A?

 

Related Reports

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/

Categories